AbbVie Inc. ABBV

NYSE · Healthcare · Drug Manufacturers - General

$286.20

Close on Fri, 20 Nov 2026 · market value $506B

What the price is betting on

Below its record

At $286, the price assumes revenue grows about 3.2% a year for five years, from $66B to about $75.4B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes3.2%
Analysts, next two years8.8%
Last 3 years7.4%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than ABBV? Check up to 5 of your stocks at once, free, no account.

0$25B$50B$75B$100B$66B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$315

Base

$379

Bull

$456

Today $286

  • Bear $315. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $379. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $456. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$66.5B$67.7B, on the path
  3. FY2027$68.6B$73.8B, on the path
  4. FY2028$70.8B$79.7B, on the path
  5. FY2029$73B$84.2B, on the path
  6. FY2030$75.4B$86.4B, on the path

Each year's revenue at 3.2% growth from $66B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - General · listed on NYSE

Revenue, FY2025
$61.2B
Growth, 3 years a year
7.4%
Cash margin
29%
Net debt
$63.8B
Shares, 3-year change
−0.2%
Dividend yield
2.3%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.